Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL934840 | 1.00 | GPR119 (0.35) | GPR119EPHX2USP2SMN1; SMN2CTSK | |
| SCHEMBL25228618 | 0.94 | CTSK (0.35) | GPR119EPHX2SMN1; SMN2CTSKHSD17B10 | |
| SCHEMBL933183 | 0.94 | CTSK (0.35) | GPR119EPHX2SMN1; SMN2CTSKHSD17B10 | |
| SCHEMBL25281618 | 0.93 | HPGD (0.36) | GPR119EPHX2SMN1; SMN2CTSKHSD17B10 | |
| SCHEMBL25274718 | 0.91 | USP2 (0.42) | GPR119EPHX2USP2SMN1; SMN2KDM1A | |
| SCHEMBL25238047 | 0.88 | GPR119 (0.35) | GPR119EPHX2HSD17B10KDM1ADDB1 | |
| SCHEMBL935288 | 0.87 | NR1H2 (0.34) | GPR119EPHX2USP2SMN1; SMN2CTSK | |
| SCHEMBL26782806 | 0.87 | NR1H2 (0.34) | GPR119EPHX2USP2SMN1; SMN2CTSK | |
| SCHEMBL935289 | 0.87 | NR1H2 (0.34) | GPR119EPHX2USP2SMN1; SMN2CTSK | |
| SCHEMBL9003330 | 0.85 | EPHX2 (0.35) | EPHX2USP2SMN1; SMN2CTSKHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114057740-B | Spiropyrimidinone derivatives, method for the production thereof, pharmaceutical compositions and use thereof | 上海赛默罗生物科技有限公司 | 2024-04-02 | — | — | CN | disclosed |
| WO-2023109471-A1 | SPIRO PYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 上海赛默罗生物科技有限公司 | 2023-06-22 | — | — | WO | disclosed |
| WO-2023109471-A1 | SPIRO PYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 上海赛默罗生物科技有限公司 | 2023-06-22 | — | — | WO | disclosed |
| CN-114057740-A | Spirocyclic pyrimidone derivatives, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2022-02-18 | — | — | CN | disclosed |
| EP-2454252-B1 | Spiro amino compounds suitable for the treatment of (inter alia) sleep disorders and drug addiction | Rottapharm Biotech Srl (IT) | 2015-03-04 | — | — | EP | disclosed |
| US-8859608-B2 | Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction | ROTTAPHARM BIOTECH S.R.L. (IT) | 2014-10-14 | — | — | US | disclosed |
| US-8859608-B2 | Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction | ROTTAPHARM BIOTECH S.R.L. (IT) | 2014-10-14 | — | — | US | disclosed |
| US-8859608-B2 | Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction | ROTTAPHARM BIOTECH S.R.L. (IT) | 2014-10-14 | — | — | US | disclosed |
| US-20120115882-A1 | SPIRO AMINO COMPOUNDS SUITABLE FOR THE TREATMENT OF INTER ALIA SLEEP DISORDERS AND DRUG ADDICTION | ROTTAPHARM BIOTECH S.R.L. (IT) | 2012-05-10 | — | — | US | disclosed |
| US-20120115882-A1 | SPIRO AMINO COMPOUNDS SUITABLE FOR THE TREATMENT OF INTER ALIA SLEEP DISORDERS AND DRUG ADDICTION | ROTTAPHARM BIOTECH S.R.L. (IT) | 2012-05-10 | — | — | US | disclosed |
| US-20120115882-A1 | SPIRO AMINO COMPOUNDS SUITABLE FOR THE TREATMENT OF INTER ALIA SLEEP DISORDERS AND DRUG ADDICTION | ROTTAPHARM BIOTECH S.R.L. (IT) | 2012-05-10 | — | — | US | disclosed |
| WO-2011006960-A1 | SPIRO AMINO COMPOUNDS SUITABLE FOR THE TREATMENT OF INTER ALIA SLEEP DISORDERS AND DRUG ADDICTION | ROTTAPHARM S.P.A. (IT) | 2011-01-20 | — | — | WO | disclosed |
| WO-2011006960-A1 | SPIRO AMINO COMPOUNDS SUITABLE FOR THE TREATMENT OF INTER ALIA SLEEP DISORDERS AND DRUG ADDICTION | ROTTAPHARM S.P.A. (IT) | 2011-01-20 | — | — | WO | disclosed |
| EP-2275421-A1 | Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction | Rottapharm S.p.A. (IT) | 2011-01-19 | — | — | EP | disclosed |
| EP-2275421-A1 | Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction | Rottapharm S.p.A. (IT) | 2011-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115882-A1 | SPIRO AMINO COMPOUNDS SUITABLE FOR THE TREATMENT OF INTER ALIA SLEEP DISORDERS AND DRUG ADDICTION | SLC1A1, SLC6A3, SLC1A2 | GPR119 1007/4885EPHX2 2465/4885USP2 4822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.